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Abstract
In this paper we present a framework for the reduction and linking of physiologically based pharmacokinetic (PBPK)
models with models of systems biology to describe the effects of drug administration across multiple scales. To address the
issue of model complexity, we propose the reduction of each type of model separately prior to being linked. We highlight
the use of balanced truncation in reducing the linear components of PBPK models, whilst proper lumping is shown to be
efficient in reducing typically nonlinear systems biology type models. The overall methodology is demonstrated via two
example systems; a model of bacterial chemotactic signalling in Escherichia coli and a model of extracellular regulatory
kinase activation mediated via the extracellular growth factor and nerve growth factor receptor pathways. Each system is
tested under the simulated administration of three hypothetical compounds; a strong base, a weak base, and an acid,
mirroring the parameterisation of pindolol, midazolam, and thiopental, respectively. Our method can produce up to an 80%
decrease in simulation time, allowing substantial speed-up for computationally intensive applications including parameter
fitting or agent based modelling. The approach provides a straightforward means to construct simplified Quantitative
Systems Pharmacology models that still provide significant insight into the mechanisms of drug action. Such a framework
can potentially bridge pre-clinical and clinical modelling - providing an intermediate level of model granularity between
classical, empirical approaches and mechanistic systems describing the molecular scale.
Keywords Mathematical pharmacology  Model reduction  Systems pharmacology  PBPK
Introduction
Within the past decade quantitative systems pharmacology
(QSP) has emerged as a novel discipline proposing the use
of integrated, multidisciplinary models that bridge the gap
between the biological insight of modelling target scale
effects of drug action systemically with pharmacokinetic/
pharmacodynamic (PKPD) modelling approaches tradi-
tionally found in the field of clinical pharmacology
[49, 59, 61, 65]. The aim of such an approach is to obtain
mechanistic models of drug action that enable the predic-
tion of drug dose-exposure, efficacy and potential side
effects for a given subject and dose a priori. Some
researchers [60] see the approach as providing a partial
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the pharmaceutical industry and a stepping stone towards
an ultimate goal of personalised medicine.
The core principle of QSP is the bringing together of
data and knowledge from basic biological research and the
multiple stages of drug development into a single multi-
scale quantitative modelling framework describing drug
action. At its simplest this means the integration of cell
level signalling detail (e.g. protein-protein interaction net-
works) with multiscale models that span the effect of drug
binding at the molecular level up to the whole-body effects
of drug administration, absorption and clearance. The
approach has a number of potential benefits compared with
empirical compartmental modelling approaches commonly
used to describe population PKPD. Firstly, it offers an
integrated modelling approach to drug development
bringing together experimental results from preclinical,
animal and clinical studies into a unified quantitative model
of drug action, enabling a more mechanistic approach to
the study of translation. Secondly, it can provide greater
insight into the mechanisms of action underlying drug
efficacy and toxicity, with mathematical analysis of
molecular scale signalling models potentially enabling the
study and prediction of emergent cell scale network phe-
nomena that may not have been predictable via traditional
PKPD approaches. Thirdly, it can yield better mechanistic
understanding of the possible causes of between-patient
variability. Finally, it enables the integration of data from
previous drug candidates of similar classes (failures and
successes) that act on the same or related pathways. In
doing so, it can provide a more nuanced framework for
studying the causes of drug candidate failure and how they
can be avoided in future.
Whilst QSP offers an approach for integrating knowl-
edge across multiple scales in the prediction of drug effi-
cacy, it raises a number of mathematical challenges [61].
These include developing the tools to create and validate
multiscale models potentially ranging from the genetic to
population level, surmounting the issues of practicability
associated with highly complex, nonlinear models of bio-
chemical reaction cascades, and addressing the general
difficulties associated with meaningfully combining inter-
disciplinary data. In this paper we outline a framework for
the creation of QSP models through the reduction and
linkage of physiologically based pharmacokinetic (PBPK)
models with reduced systems biology type models
describing the biochemical activity of a drug at the cellular
and intracellular scales.
Pharmacological modelling of drug disposition now
commonly employs PBPK at multiple stages of research
and development [17, 18, 32]. Such systems describe the
movement of a drug throughout compartments corre-
sponding to realistic tissues that span the entire body.
PBPK models differ from the classical compartmental
approaches to pharmacokinetic modelling in that they
incorporate parameters informed via physiological and
biological knowledge of the body in order to more mech-
anistically, as opposed to empirically, describe pharma-
cokinetic activity. Due to the higher dimensionality of
these models, and associated issues of parameterisation to
which such a modelling approach can lead, PBPK remains
most commonly applied within the context of drug dis-
covery and for the scaling of in vitro or animal studies of
drug disposition. At clinical stages of drug development,
PBPK can still find use in drug-drug interaction or pediatric
studies, but where clinical trials are performed in order to
initially fit models to in vivo experimental data, simpler
and more empirical approaches to PK modelling still tend
to be preferred. In part, this is due to the fact that PBPK
models are often found to be structurally unidentifiable
[64], greatly hindering their practical use in the context of
clinical trial data. Partly in order to improve such proper-
ties of identifiability and to enable parameter fitting, pub-
lications concerning the reduction of PBPK models, have
begun to emerge [57].
As an approach to mathematically modelling biological
systems, systems biology differs philosophically from
preceding approaches in that it attempts to describe cells
and their signalling systems holistically [19, 20]. This
enables the creation of models that incorporate explanatory
power of underlying biological mechanisms at the cost of
significant model complexity. This is typically achieved by
describing systems at a molecular level of detail and
showing how their interaction can produce larger scale
phenomena of interest. Such approaches have gained some
traction within a pharmacological setting due to their
capacity to describe a drug’s mechanism of action
physiologically.
By combining PBPK and systems biology modelling
approaches, it is hence hypothetically possible to model
drug disposition and dose-response mechanistically as
opposed to the traditionally empirical description provided
by classical PKPD. Rather than fitting an abstract model to
the clinically observed data, the aim here is to produce a
model that describes in detail the main physiological pro-
cesses at work. This leads to a multiscale modelling
approach spanning the scales and processes depicted, for
example, in Fig. 1. Here, a PBPK model describes the
absorption, distribution and clearance of the drug through
the body, whilst in a given effective compartment a Sys-
tems Biology type model describes how the effective
concentration of the drug elicits a response at the target
scale. Figure 1 shows a receptor type target of drug bind-
ing, but the general idea is valid across many target types.
Despite their potential usefulness, however, models
attempting to span the scales of both PBPK and systems
biology will typically be significantly too complex to be of
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practical use in a clinical setting. This complexity can be
seen to stem from a number of common mathematical
properties. For instance, such models will often possess a
very large number of modelled species, concentrations and
reactions. Such systems are often modelled using the the-
ory of deterministic ordinary differential equations (ODEs)
and as such can comprise tens to hundreds of state-vari-
ables. Such models thus often come with associated issues
of high simulation time and numerical error. Models also
frequently describe a wide range of kinetic rates observed
across the multiple scales of drug action and as a result,
portions of the system are likely to evolve on greatly dif-
ferent time-scales resulting in model stiffness. Such models
are also usually nonlinear, which can prohibit a number of
analytical approaches. Finally, due to the scope of these
systems, it can simply prove too difficult to readily intuit or
understand their biological implications. Often the param-
eter space is simply too large to convincingly explore or
understand what variation in the parameterisation may
mean.
One methodology for tackling a number of these issues,
in an effort to bring understanding of the role of processes
within and across scales, is model reduction. Model
reduction here refers to any method designed to construct a
simplified formulation of a model with which some set of
the original dynamical behaviour can be satisfactorily
approximated and within which some degree of predictive
power is retained. A wide variety of such methods exist in
the literature [2, 34, 47] and they have commonly been
employed for alleviating issues of complexity in other
fields of modelling (for example chemical engineering
[34], control theory [44], and weather prediction [26]).
Within the context of integrative QSP, model reduction can
potentially be applied at multiple levels. In this paper we
evaluate two particular uses in this context; firstly, model
reduction can be used to yield a simplified description of
the pharmacokinetic disposition of a drug that retains a
physiological basis. Secondly, it be can be used to produce
a reduced description of the biochemical activity of the
drug at the target scale through the simplification of sys-
tems biology type models.
The simplification of PBPK models has been relatively
well explored in the literature through the use of linear,
proper lumping [4, 10, 12, 33, 37]. The aim is typically to
reduce the more complex models of PBPK to the point
where they can be fit against clinical trial data as in the case
of traditional compartmental PK models [57]. Proper
lumping has also seen application in the broader contexts
of Systems Biology [7, 9, 21, 50, 51] and Systems Phar-
macology [14] type models. Other model reduction
approaches including time-scale exploitation
[6, 13, 22, 23, 36, 39, 43, 52–54], sensitivity analysis
[3, 8, 28, 29, 45], optimisation based approaches
[1, 30, 38, 55] and balanced truncation [15, 27, 48] have
also seen published application within a systems biology
setting. Here, we focus specifically on two of these meth-
ods - proper lumping and balanced truncation. Proper
lumping seeks to reduce a system by modelling the
dynamical behaviour of subsets of the original state-vari-
ables en masse as opposed to individually. Meanwhile
balanced truncation transforms the model’s state-variables
into a form where those portions of the network least
responsible for some input–output type relationship of
interest can be easily removed.
The ideal scope and complexity of model depends
necessarily on the specific questions that we are seeking to
address, the level of approximation we are willing to
accommodate, the prior knowledge we have at hand, and
the actual data available. In practice, modelling often boils
down to a balance between these factors. When con-
structing models from the ground up, these considerations
often have to be repeatedly assessed—and discussions
around how to achieve this do exist in the literature [63].
One of the key advantages of model reduction, however, is
Fig. 1 Multiple scales of drug action. Our approach seeks to bring
together models from across multiple scales of drug action into a
single framework. Here the whole body scale is represented by a
model of pharmacokinetics, where the effective compartment (in this
case the tissue) comprises a model of diffusing drug molecules. The
molecular or target scale incorporates a description of drug-receptor
binding and the underlying signalling cascade dynamics (the systems
biology scale). The example given here applies to G protein-coupled
receptor type drugs targets, but the approach is valid more generally
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that we can instead start by constructing a complex model
based upon the full extent of the literature available, and
then use automated methods to reduce it down to a scale
appropriate to its intended application. It is this approach
that we seek to leverage throughout this paper—by first
assembling a holistic, physiological description of a drug’s
mechanism of action alongside its pharmacokinetic dispo-
sition, we then aim to apply model reduction to the indi-
vidual components of this model in order to automatically
extract a practical and usable system that retains an explicit
link back to this physiological scale.
The literature concerning the other step of linking of PK
modelling efforts with those of systems biology is less
developed than that of model reduction. Krippendorff et al.
[24] have demonstrated a simple linking procedure
whereby a mass-action model is built integrating the
whole-body and cellular scales. Both normal and diseased
cells exist in a well-stirred compartment of the PK model
each with receptors able to bind to the drug. They
demonstrate that this approach can potentially be used to
study how such differences in receptor affinity affects the
clinical response of drugs with the same proposed mech-
anism of action. It is this approach to model linkage that we
employ throughout our work.
Given the context outlined above, our paper demon-
strates how methods of model reduction and model linkage
can be brought together under a single framework in order
to yield simplified Systems Pharmacology or enhanced
pharmacodynamics models [16]. The developed method-
ology is applicable to models formulated using determin-
istic nonlinear and linear ODEs. For a given drug, the
framework presented here starts with a model of PBPK and
a relevant systems biology model describing the drug’s
hypothesised mechanism of action at the target scale. The
approach applies differing methods of model reduction to
individual components of the network based on their suit-
ability, and then recombines the reduced components to
finally obtain a simplified system. This work is related to
our previous paper [46] which developed a combined
model reduction algorithm that sequentially applied mul-
tiple methods of reduction in order to obtain highly accu-
rate reduced systems.The overall method, however, does
not sequentially apply reduction methods, but instead seeks
to decompose the overall network into linear and nonlinear
sub-modules and then reduce them independently using the
most appropriate method for each. By focusing on the
maintenance of input–output relations for each sub-module
throughout its reduction, we allow the overall model to
remain highly accurate when recombined. As is demon-
strated, these models continue to provide an accurate
description of drug action across multiple scales whilst also
having been reduced to a significantly more tractable size.
Additionally, our approach in the reduction of PBPK
models is differentiated from those previously published in
that we seek to apply balanced truncation, as opposed to
proper lumping, as a means of simplification. The frame-
work is demonstrated using a generalised PBPK model and
systems biology models of differing complexity: an 11
dimensional model of bacterial chemotactic signalling in
Escherichia coli [56] and a 99 dimensional model of
extracellular signal-regulated kinase (ERK) phosphoryla-
tion mediated via the epidermal growth factor (EGF) and
nerve growth factor (NGF) receptor pathways [42].
Methodology
There are several possible approaches for the creation of a
reduced model spanning the multiple scales of drug
activity. This paper assumes that one begins with, or is able
to develop, models of the drug’s pharmacokinetic beha-
viour and the target scale activity describing its proposed
mechanism of action. The aim is then to create a single
system encapsulating the dynamics of both models whilst
also being simple enough to be practically usable within a
clinical setting.
Given this starting point, the overall aim is comprised of
two major steps; model reduction and model linkage. There
are two possible routes to achieving this:
1. Linking the models together initially and reducing the
entire linked system under a single approach to obtain
the reduced linked system; or
2. Initially seeking to separate or decompose the con-
stituent models into sub-modules with related proper-
ties. Then, seek to reduce these modules in isolation,
using the most appropriate method of reduction for
each model component. Finally we can then link the
reduced modules together, again yielding a reduced
linked system.
Whilst the first approach may allow a simpler mathe-
matical implementation by only requiring a single model
reduction approach, this fact is also its main disadvantage
in that the method employed must be valid for all aspects
of the model and is unlikely to be optimal for any of them.
Instead this paper outlines the use of the second approach,
which allows us to tailor the methods of model reduction to
specific model components and hence obtain better, more
accurate overall reduced systems. The reasons for wanting
to achieve this are twofold.
Firstly, although models of PBPK are often nonlinear,
they can often be decomposed into linear and nonlinear
components. The linear components would typically
include a description of the inter-compartmental distribu-
tion of the drug throughout various tissues of the system,
whilst the nonlinear components tend to include intra-
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compartmental components (covering examples such as
Michaelis-Menten like metabolism in the liver, saturable
plasma protein binding, and interaction with transporters or
target-mediated drug disposition within some effective
compartment). These nonlinear components can often be
‘disintegrated’ from the linear model, and intead repre-
sented by arbitrary input and output terms within the linear
network. Similar decomposition approaches have previ-
ously been described in the area of modular response the-
ory and applied to systems biology type models to good
effect [5, 27]. An example of such a decomposition is
presented in Fig. 2. Given such a decomposition it is
possible to employ more efficient, linear methods of model
reduction that globally preserve the input–output relation-
ship of the system (such as balanced truncation) for the
reduction of the linear portion of the network.
Secondly, the timescales of PBPK models are typically
significantly slower than those of biochemical reaction
network models. As a result, reduction of the pre-linked
system will often remove much more of the detail from the
systems biology model which may not be ideal in the case
where mechanistic explanatory power at this scale is
intended to be retained.
The overall approach for achieving a reduced linked
system proposed here is depicted in Fig. 3b. The method
begins with the unreduced PBPK and systems biology
intracellular biochemical reaction network models. To
reduce the PBPK model we then decompose it into its
linear and nonlinear components as previously described.
Inputs and outputs are then defined based upon this
decomposition, the specific modelled phenomena of inter-
est, and to represent how the PK drives the modelled sys-
tems biology processes. Next the linear components of the
model are reduced via balanced truncation under the
defined input–output terms. All nonlinear components,
typically including the biochemical reaction network, are
then reduced via proper lumping. Finally, the reduced
model components are then linked.
Crucially, points of coupling between models or model
components, as well as any imposed model linkages, can
be addressed by defining the outputs of one model or
component to represent the inputs of those it affects; an
example of which is given in Fig. 2. The reduced models
are then constructed so as to be able to maintain this input–
output behaviour, thus guaranteeing the relative accuracy
of the reduced ensemble of models when recombined.
Once constructed, the performance of such reduced linked
systems can be compared to the ‘unreduced linked system’
as depicted in Fig. 3a.
Given this overall framework, the remainder of this
methodology section provides more specific, mathematical
detail on the overall problem and a basic account of the
reduction methods – proper lumping and balanced
truncation.
Model reduction and approximation error
Throughout this paper we seek to reduce both PBPK and
Systems Biology type models. In both cases such physical
systems are generally described by systems of coupled,
nonlinear ODEs. For our purposes here, we additionally
formulate these systems as initial value problems and
express them via a control affine, state-space representation
such that
A B
Fig. 2 Example depiction of a linear/nonlinear decomposition of a
PBPK model. a Depicts an example schematic of a PBPK model,
which includes some nonlinear description of metabolism occurring
in the liver compartment. Here inputs u1ðtÞ and u2ðtÞ refer to the time-
courses of IV doses and oral doses respectively. b Shows how the
model can be decomposed into linear and nonlinear components. y1ðtÞ
represents an output of the linear portion of the model which feeds
into the liver compartment, and u3ðtÞ is an input into the model,
representing the distribution of the drug from the liver to the venous
compartment
Journal of Pharmacokinetics and Pharmacodynamics
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_xðtÞ ¼ f ðxðtÞÞ þ
Xl
i¼1
giðxðtÞÞuiðtÞ; ð1aÞ
yðtÞ ¼ hðxðtÞÞ; ð1bÞ
with initial conditions xð0Þ ¼ x0 and where the over-dot
represents the time-derivative (such that, _x ¼ dx
dt
). Here
xðtÞ 2 Rn represents the model state-variables (e.g. the
time-varying concentrations of the modelled species or the
compartmental drug concentrations), uðtÞ 2 Rl (such that
uiðtÞ 2 uðtÞ) represent the input variables (e.g. the initial,
repeated or continuous doses that are mapped to the rele-
vant pharmacokinetic compartments), and y 2 Rp represent
the output variables. Here, fðxðtÞÞ is the set of functions
describing the dynamical interaction between the state-
variables, each set of functions giðxðtÞÞ describes how the
inputs feed into the state-variable dynamics and hðxðtÞÞ
describes the combinations of the state-variables corre-
sponding to each of the outputs. Note that in the linear case,
common in the study of pharmacokinetics, the original
system (1) can be expressed in the form
_xðtÞ ¼AxðtÞ þ BuðtÞ; ð2aÞ
yðtÞ ¼CxðtÞ; ð2bÞ
where A, B, and C are linear operators, such that
A : Rn ! Rn, B : Rl ! Rn and C : Rn ! Rr.
Whilst model input and output can be fairly abstract
concepts, within a pharmacological context they can be
reasonably concretely understood. In the case of a PBPK
type model the input could, for example, describe the
dosing regimen administered, whilst the output might
correspond to the concentration of the compound in some
subset of the modelled compartments. In the case of a
systems biology type model describing a receptor sig-
nalling pathway, the input might represent the time-vary-
ing, extracellular concentration of a specific ligand, whilst
the output may represent the concentration of a specific
intracellular protein associated with a cellular response of
interest.
Given such a formulation, we then seek a reduced model
of the form
_~xðtÞ ¼ ~f ð~xðtÞÞ þ
Xl
i¼1
~gið~xðtÞÞuiðtÞ; ð3aÞ
yðtÞ ¼ ~hð~xðtÞÞ; ð3bÞ
A BFig. 3 Proposed schematics for
the reduction and linking of
PBPK and systems biology
modelling approaches.
a Depicts a schematic for the
creation of what is here referred
to as the ‘unreduced linked
model’. b Depicts the
recommended schematic for the
creation of what is here referred
to as the ‘reduced linked
model’. Circles indicate a
methodology to be applied
whilst the rounded rectangles
indicate the type of model
thereby produced
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where  denotes an approximation of reduced dimension
for the equivalent, original term in Eq. (1). Additionally,
yðtÞ 2 Rp represents an approximation of the original out-
put y calculated from the values of the reduced state-
variables ~x.
The accuracy of the reduced models can be quantified
by a number of approaches, often dependent upon the
specific aims of reduction. The most common approaches
are based upon measures of the instantaneous error
between the outputs of the two systems, yðtÞ  yðtÞj j.
Throughout this paper we use a measure of maximal rel-
ative error e, such that
e ¼ yðtÞ  yðtÞk k1
yðtÞk k1
: ð4Þ
Here, the relative error is selected such that the accuracy of
the reduced models can be compared across a range of
different inputs and initial conditions whilst retaining the
same relative meaning.
It is important to note that all model reduction will result
in some degree of error e. As a result the specific choice of
reduced model to use in a given situation essentially boils
down to a compromise between simplicity and accuracy.
Inevitably this choice will depend upon the specific aims
and context associated with the modelling work being
performed, and as such it is hard to give a catch-all rule for
choosing the best level of reduction to employ. In this
paper we have selected the target of 5% error for our
reduced linked models, and aimed to construct the minimal
dimensional model that remains within this degree of error.
Proper lumping
Proper lumping is a method of model reduction which
seeks to create a lower dimensional representation of a
system by partitioning the state-variables xðtÞ into subsets,
and modelling the dynamics of these subsets en masse.
This is achieved via a linear operator L : Rn ! Rn^ that can
be applied to the original state-variables, such that
~xðtÞ ¼ LxðtÞ; ð5Þ
where ~xðtÞ 2 Rn^ represents a reduced set of state-variables,
with n^\n. Given such a lumping matrix L, a more detailed
mathematical account of how to obtain the reduced,
dynamical description of the model under this projection
can be found in Appendix 2.
There is a range of literature describing different
approaches for finding the optimal lumping matrix L to
produce a reduced system of dimension n^ for a given
system. Here we employ the scheme described by Dok-
oumetzidis and Aarons [9]. This algorithm runs an
exhaustive search of possible lumping matrices to
determine which produces the lowest error between simu-
lation of the original model and the reduced model. To
speed up this process, it is assumed (from justifications
given in the original paper) that the lowest error k dimen-
sional reduction obtained via lumping of an n dimensional
system can also be found as the optimal lumping of two
states in the k þ 1 dimensional reduction. This yields a
‘forward selection’ strategy, where 2 of the state-variables
are lumped at each step, which greatly decreases the
combinatorial burden of possible lumping matrices that
must be evaluated.
Balanced truncation
Balanced truncation is a method of model reduction for the
simplification of systems describing an input–output type
process. It is most commonly employed in the field of
control theory and was originally devised in the early
1980s [31]. The method was further refined by a number of
authors (e.g. [35]) and has subsequently become a well-
developed one [11, 44]. Typically, it is used in the sim-
plification of time-invariant, linear systems and seeks to
remove those portions of the dynamics that contribute least
to the overall input–output relationship of the model. As
such it begins with systems in the form of Eq. (2) and
assumes that A is a stable or Hurwitz matrix, such that its
eigenvalues all have negative real components. This
implies that the system is asymptotically stable; a property
that will typically hold true for all biochemical systems.
Central to the application of balanced truncation to such
a system are the concepts of observability and controlla-
bility. Broadly speaking, controllability asks to what
degree the state-variables xðtÞ of the system can be
‘moved’ or affected by the input uðtÞ. Meanwhile observ-
ability asks to what degree the state-variables of the system
can be inferred or ‘observed’ from the output yðtÞ. Both
concepts go some way to addressing a crucial question; to
what extent and by what means does the input into the
system affect its output?
To quantify these concepts requires the calculation of
two matrices known as the controllability and observability
Gramians (P and Q, respectively) for the system. Once
obtained, the aim is to find a balancing transformation for
the system. This is a transformation of the state-variables
for which the Gramians are equalised and diagonalised and
which can be achieved via use of the singular value
decomposition. As a result, the state-variables produced by
such a transformation are somewhat obfuscated in terms of
their meaning with respect to the original model. Much like
other singular value decomposition based methodologies,
such as the statistical method of principle component
analysis, they instead represent orthogonal directions in
state-space that, when treated as the new variables of our
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system, describe the input–output behaviour in order of
contribution. Thus the first transformed state-variable
accounts for the largest contribution to the input–output
relationship and each succeeding component in turn
describes the most of the input–output behaviour possible
under the constraint that it is orthogonal to the preceding
state-variables. By omitting or ‘truncating’ the transformed
state-variables that contribute least to the input–output
relationship we can construct a reduced model whilst los-
ing only relatively little accuracy.
Whilst the state-variables themselves are obscured, it is
always possible to obtain an accurate description of any of
the defined outputs and there is no limit on the outputs that
can be defined. This is achieved via use of a generalised
right inverse, that, when applied to the reduced state-vari-
ables can be used to recover approximations of the original
outputs based upon the reduced system.
Such an approach has significant advantages over proper
lumping; firstly, it is designed for an input–output formu-
lation which fits well within a pharmacokinetic context.
Secondly, as is shown in Dullerud and Paganini [11], an a
priori error bound can be obtained for reduction under
balanced truncation. A more detailed description of the
mathematical steps needed to calculate and apply such a
balanced truncation is given in Appendix 3.
Results and discussion
Reducing a PBPK model
Here we demonstrate the application of balanced truncation
in reducing a PBPK model. This serves two purposes.
Firstly, it allows us to reduce the model in preparation for
linking with a Systems Biology type model. Secondly, it
allows us to compare reduction via balanced truncation
with the more commonly employed approach of proper
lumping.
A number of general frameworks for modelling PBPK
have been described in the literature. Here we employ the
model published by Jones and Rowland-Yeo in their recent
review of PBPK modelling [17] and shown in Fig. 4. This
model describes the movement of a drug between sixteen
physiological compartments – adipose tissue, bone, the
brain, the gut, the heart, the kidneys, the liver, the lungs,
muscle tissue, the skin, the spleen, the testes, venous blood,
arterial blood, an oral dosing compartment and a single
compartment representing the remainder of the body. A
detailed account of this PBPK model and its reduction are
given in Additional file 1 - Supplementary Information.
Here we consider this general model within a control
theoretic framework as earlier described by Eq. (1). When
trying to understand how the administration of a particular
drug propagates throughout the body, such a formulation of
the problem represents a logical framework for its
description. Mathematically, this model can therefore be
represented by a 16 dimensional system of non-conserved,
linear ODEs, which can be expressed in the form described
by Eq. (2). In this case A 2 R1616 is a matrix representing
the kinetic rates with which the concentration of drug
moves between the compartments and x 2 R16 represents
the vector of instantaneous drug concentrations in each of
the physiological compartments. Our inputs, uðtÞ, represent
the times and magnitudes of the doses administered. These
doses are then mapped to the compartments to which they
contribute by the matrix B. For instance, an orally admin-
istered drug would be mapped directly to the oral dosing
compartment. The outputs, yðtÞ, and their mapping C from
the original compartment concentrations are those combi-
nations of the compartments that the modeller seeks to
predict with the system. It is possible to simply set C equal
to the identity matrix such that all compartments are con-
sidered, however it is often the case that only some subset
of the compartments (often the intravenous and effective
compartments) are of clinical relevance.
Crucially to PBPK modelling, the specific values and
form of the matrix A depends upon the model’s particular
parameterisation. For models of this type, the parameters
can be split into two sets.
Set 1: The physiological parameters, found in Table 1.
These parameters represent the various physio-
logical properties of the individual to which the
drug is administered. The values presented here
represent a 70 kg male human with average
measures of liver and kidney function, fractional
tissue volumes, and blood flow from Jones and
Rowland-Yeo [17].
Set 2: The compound-specific parameters, found in
Table 2. These parameters represent specific
properties of the drug that has been administered.
Parameterisations for three specific compounds
across a reasonable pH range are given here: a
strong base represented by the beta-blocker
pindolol, a weak base represented by the benzo-
diazepine midazolam, and an acid represented by
the barbiturate thiopental. Compound specific
parameters were taken from Pilari and Huisinga
[4]. Tissue to plasma partition coefficients were
then estimated via the formulae outlined by
Rodgers et al. [40, 41].
We now seek to apply balanced truncation for the
reduction of this system as compared with the linear,
proper lumping approach as described by Pilari and Hui-
singa [4] which employs the algorithm originally
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developed by Dokoumetzidis and Aarons [9]. To test the
application of balanced truncation we sought to reduce the
model described above by treating the concentration of the
drug in the venous compartment as the only output of
interest. The dose was modelled as being orally adminis-
tered in each case, with the timing and magnitude of these
doses representing the model input. Given this framework,
calculating reduced versions of the model via both proper
lumping and balanced truncation under the given com-
pound specific parameters yields the results given in
Table 3.
As can be seen, balanced truncation provides good
reduction results even down to 3 dimensions and can often
produce more accurate reductions than those obtained
under lumping. Figure 5 compares the 3 dimensional
reduced models obtained under balanced truncation and
lumping to the original system; here, across the 3 com-
pounds, the lumped reduction had an average maximal
relative error of 19.3% whilst balanced truncation was able
to attain an error of only 7.1%.
Table 1 Physiological
parameters for the PBPK model
shown in Fig. 4, their meaning,
and the values used
Parameter Meaning Value
BW Body weight (kg) 70
QC Cardiac output (L/h) 3:90 102
MPPGL mg microsomal protein per g liver 45
FVad Fractional volume of adipose (L/kg) 2:13 101
FVbo Fractional volume of bone (L/kg) 8:56 102
FVbr Fractional volume of the brain (L/kg) 2 102
FVgu Fractional volume of the gut (L/kg) 1:71 102
FVhe Fractional volume of the heart (L/kg) 4:7 103
FVki Fractional volume of the kidneys (L/kg) 4:4 103
FVli Fractional volume of the liver (L/kg) 2:1 102
FVlu Fractional volume of the lungs (L/kg) 7:6 103
FVmu Fractional volume of muscle (L/kg) 4 101
FVsk Fractional volume of skin (L/kg) 3:71 102
FVsp Fractional volume of the spleen (L/kg) 2:6 103
FVte Fractional volume of testes (L/kg) 1 102
FVve Fractional venous volume (L/kg) 5:14 102
FVar Fractional arterial volume (L/kg) 2:57 102
FVpl Fractional volume of plasma (L/kg) 4:24 102
FVrb Fractional volume of red blood cells (L/kg) 3:47 102
FVre Fractional volume of rest of body (L/kg) 9:98 102
FQad Fractional adipose blood flow 5 102
FQbo Fractional bone blood flow 5 102
FQbr Fractional brain blood flow 1:2 101
FQgu Fractional gut blood flow 1:46 101
FQhe Fractional heart blood flow 4 102
FQki Fractional kidney blood flow 1:9 101
FQh Fractional hepatic blood flow (venous) 2:15 101
FQlu Fractional lung blood flow 1
FQmu Fractional muscle blood flow 1:7 101
FQsk Fractional skin blood flow 5 102
FQsp Fractional spleen blood flow 1:72 102
These values represent a 70 kg male human with average measures of liver and kidney function, fractional
tissue volumes and blood flow. Fractional volumes represent the rough volume of each tissue proportional
to overall bodyweight and the tissue specific fractional blood flows are proportional to the overall cardiac
output. Parameter values are sourced from Jones and Rowland-Yeo [17]
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Systems biology model reduction and linking
We now seek to demonstrate the potential application of
our model linkage and reduction methodology via appli-
cation to two example models. In the first instance we
consider an 11 dimensional model of bacterial chemotaxis
in E. coli - the modest scope of this model allows the
application of our methods to be more easily intuited. After
this we address a significantly more complex, 99
dimensional model describing the mediation of ERK acti-
vation via both the EGF and NGF receptor pathways. In
both cases we employ pindolol, midazolam and thiopental
as example compound specific parameterisations to repre-
sent a hypothetical drug acting on the pathways described.
To demonstrate our approach, we begin by first reducing
each model via lumping before linking their reduced forms
with the reduced PBPK model detailed in the preceding
section.
Table 2 Compound specific
parameters for the PBPK model
shown in Fig. 4 and their
meaning
Parameter Meaning Pindolol Midazolam Thiopental
BP Blood to plasma ratio 0.81 0.53 0.88
fup Fraction unbound in plasma 0.41 0.05 0.18
Ka Rate constant of absorption (h1) 2.08 1.13 5.64
CLbl Hepatic blood clearance (mL kg/min) 4.20 8.70 2.02
Kpad Adipose partition coefficient 1.52 2.41 12.17
Kpbo Bone partition coefficient 2.79 2.26 1.64
Kpbr Brain partition coefficient 2.26 5.12 1.09
Kpgu Gut partition coefficient 9.01 5.38 2.03
Kphe Heart partition coefficient 8.43 2.25 1.72
Kpki Kidney partition coefficient 17.94 2.51 4.85
Kpli Liver partition coefficient 16.40 2.77 3.60
Kplu Lung partition coefficient 14.11 3.33 1.72
Kpmu Muscle partition coefficient 6.08 1.61 0.78
Kpsk Skin partition coefficient 5.13 7.84 1.25
Kpsp Spleen partition coefficient 11.70 1.47 0.94
Values have been given for a strong base (pindolol), a weak base (midazolam), and an acid (thiopental).
Parameter values are sourced from Pilari and Huisinga [4] and tissue-to-plasma partition coefficients were
approximated using the formulae of Rodgers et al. [40, 41]
Table 3 Percentage maximal
relative error, e, associated with
the reduction of the PBPK
model via both lumping and
balanced truncation
Dimensions Pindolol Midazolam Thiopental
Lumping (%) BT (%) Lumping (%) BT (%) Lumping (%) BT (%)
13 0.02 0 0.02 0 0.02 0
12 0.04 0 0.02 0 0.03 0
11 0.08 0 0.03 0 0.08 0
10 0.20  0 0.27  0 0.10  0
9 0.23  0 0.43  0 0.41  0
8 0.44  0 0.57  0 1.00  0
7 4.15  0 2.41  0 3.34 0.01
6 4.72  0 2.93 0.05 12.36 0.14
5 7.94 0.21 10.47 0.18 3.88 0.14
4 15.11 0.19 3.84 1.01 21.85 4.43
3 26.87 7.86 11.29 5.41 20.03 8.13
2 37.68 72.67 19.71 10.99 77.71 40.82
1 67.13 71.17 209.29 86.79 73.80 37.78
In each case the system is simulated under the administration of a 500 mg oral dose of the respective
compound. Physiological parameters were taken to represent a 70 kg male human with average measures of
liver and kidney function, fractional tissue volumes and blood flow. Here  0% implies that oðeÞ\106
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Note that the examples discussed do not relate to
specific clinical cases of experimentally tested drugs, but
are representative of a general case. Both examples do,
however, represent receptor targets; the general method-
ology presented in this paper will work for any target type,
but receptor signalling pathways are the most common
variety of model found in the systems biology literature.
A model of bacterial chemotaxis
The first example is a model of chemotactic signalling in
E. coli outlined in a 2009 paper by Tindall et al. [56]. A
large body of literature exists around E. coli due to its
popularity within experimental settings for its ease of
growth and manipulation. It is a common, rod shaped,
gram-negative bacteria with a large number of strains
present in nature. The model discussed here pertains
specifically to those strains that exhibit a chemotactic
response. Chemotaxis is the process by which a cell senses
an environmental chemical gradient and biases its move-
ment towards those regions most suitable for growth and
reproduction. In the model presented here, this process
involves the transmembrane receptors on the surface of the
bacterium sensing the local concentrations of an attractant
or repellent; a decrease in attractant or an increase in
repellent will cause the receptors to activate a signalling
pathway inside the cell resulting in an increase of the
intracellular concentration of the phosphorylated chemo-
tactic Y protein, referred to here as CheYP. This
concentration, in turn, modulates the flagellum’s move-
ment, resulting in a change of direction for the cell.
A model of bacterial chemotaxis signalling represents a
good example to work with as:
1. The attractant-receptor binding mimics the typical
drug-receptor binding seen in QSP modelling with the
chemotactic cell response acting as the clinical
endpoint;
2. Such signalling networks are typically not overly
complex, but are large enough for model reduction to
be warranted; and
3. Chemotaxis is well characterised in the literature, and
as such models are typically fully parameterised.
Hence, it is possible to consider the external concen-
tration of the chemotactic attractant as the input into the
system and the total concentration of CheYP as the model’s
output, the latter being strongly correlated with cell
movement. Here we aim to create a linked reduced system
bringing together a reduced version of the E. coli model
with a reduced version of the PBPK model previously
described. When the model is linked with a PBPK system,
the concentration of the metabolised drug in the effective
compartment is then treated as the total extracellular
chemotactic attractant concentration. The full form of the
chemotaxis model is given in detail in Additional file 1 -
Supplementary Information.
In this instance, it was chosen that the E. coli cells were
limited to the liver and that this represented the effective
Fig. 5 A comparison of time
courses for the concentration of
venous drug in the original 16
dimensional PBPK model of
Fig. 4 with the 3 dimensional
lumped and 3 dimensional
balanced truncated reduced
models. Here the oral
administration of three
compounds—pindolol,
midazolam, and thiopental—
have been simulated under the
administration of a 500 mg
dose. Physiological parameters
were taken to represent a 70 kg
male human with average
measures of liver and kidney
function, fractional tissue
volumes and blood flow.
Parameters are detailed in
Tables 1 and 2
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compartment. In the case of the input, it was modelled that
a 150 mg dose of a chemotactic attractant was adminis-
tered orally at t ¼ 0 with the model parameterised using
those values detailed in [56]. Additionally, the PBPK
model again employed the parameterisations defined by
Tables 1 and 2, using pindolol, midazolam and thiopental
as example compound specific parameterisations.
Reducing the PBPK model via balanced truncation,
whilst seeking to preserve accuracy in the intravenous and
liver compartments, allowed a reduction of the model to 3
dimensions with a maximal relative error e (in either
compartment) of 15:6, 11:4, and 17.6% for pindolol,
midazolam, and thiopental, respectively. The chemotaxis
model was reduced through the application of conservation
analysis, used to eliminate 4 of the system’s state-variables,
followed by proper lumping under the previously described
forward selection strategy. This gave the results presented
in Table 4. Here, the 4 dimensional lumped model repre-
sents an excellent choice for further use in linking due to
the relatively large increase in reduction error seen in going
to the 3 dimensional case.
As the individual methods of reduction are designed to
preserve the input–output relationships of each model, the
reduced PBPK and chemotaxis models can then be linked in
exactly the sameway as the original systems. Specifically, by
setting an output of the PBPKmodel (the concentration of the
drug in the liver) to represent the input into the chemotaxis
model (which is defined as the extracellular concentration of
the chemotactic attractant). Hence, linking the reduced 3
dimensional PBPK system to the reduced 4 dimensional
version of the chemotaxis model yields the results given in
Fig. 6. Overall, it was possible to integrate both systems
whilst retaining amaximal relative error e of less than 4.6, 1.4
and 31% for the drug specific parameterisations of pindolol,
midazolam and thiopental respectively. Clearly the approach
provides accurate reduced models in the cases of pindolol
and midazolam, but is somewhat less convincing in repli-
cating the behaviour of thiopental; this systemwould require
us to retain a higher number of state-variables in order to
account for this drug’s faster pharmacokinetic profile. If, for
example, the reduced PBPKmodel retains a single additional
state variable (such that the PBPK model is 4 dimensional
and the overall reduced model is 8 dimensional) this maxi-
mal relative error is reduced to 4.8% giving the profile also
depicted in Fig. 6. Hence our methodology resulted in a
reduction between the unreduced linked model and the
reduced linked model from 25 state-variables to either 7 or 8
state-variables. This scale of reduction additionally yields a
speed up in simulation time – through repeated simulations
under Matlab’s inbuilt ode45 numerical solver (a 4th/5th
order Runga-Kutta solver) a roughly 80% reduction in sim-
ulation times between the unreduced and reduced linked
models was observed. For computationally intensive appli-
cations, such as parameter fitting or agent-based modelling,
such a speed up in computational time provides a substantial
benefit. The explicit equations for the reduced linked model
are given in Additional file 1 - Supplementary Information.
A model of ERK activation
The second example employed here is a model of extra-
cellular signal-regulated kinase (ERK) phosphorylation
mediated via the epidermal growth factor (EGF) and the
nerve growth factor (NGF) receptor pathways that was
originally detailed in Sasagawa et al. [42]. This biological
system commonly arises in the study of cancer and pain,
and remains an area of ongoing clinical significance. This
is a relatively large biochemical model describing 150
reactions and 99 species. It is also an interesting model in
that it integrates two receptor pathways into one, allowing
studies to be undertaken as to how they interact. Due to its
size and clinical relevance, the model represents a prime
candidate for the application of model reduction tech-
niques. The SBML representation of the Sasagawa et al.
model employed in this example is available at www.ebi.
ac.uk/biomodels-main/BIOMD0000000049.
The total concentration of phosphorylated ERK, either
in isolation or in complex, was considered as the model
output. Meanwhile, EGF binding was chosen to represent
the input under consideration, such that only one of the
pathways described in the initial model is assumed to have
a significant effect on the output of interest, therefore
providing a significant opportunity for reduction. The ini-
tial condition of the system was set to be the steady-state of
the network without any input. Given this framework, the
model was reduced through a combination of conservation
Table 4 Error results for the application of proper lumping to the
E. coli chemotaxis model
Model dimensions Lumping error (%)
6 0.15
5 0.51
4 0.54
3 4.77
2 12.88
1 75.56
The errors stated represent the maximal relative error between the
outputs of original and reduced systems, relating to the total con-
centration of phosphorylated chemotactic protein Y. In order to
ascertain the best lumping at a given dimensionality of reduction a
wide range of attractant concentrations were tested, here however we
have obtained representative error values by simulating the system
under the introduction of a 10 lM concentration of attractant ligand at
t = 0. This is based upon the original paper introducing the chemo-
taxis model [56] and the representative ligand concentration given
there
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analysis and proper linear lumping. Conservation analysis
was applied by finding the left-null space of the model’s
associated stoichiometry matrix under the approach of QR-
factorisation by Householder reflections outlined by
Vallbhajosyula et al. [58]. This revealed 23 conservation
relations enabling the reduction of the system to 76 state-
variables. Proper lumping via the forward selection strat-
egy as described in the methodology was then applied,
yielding the results presented in Table 5.
In the case of the PBPK model, it was assumed that the
therapeutic compartment of interest was the brain and that
a dose of an antagonist that binds with the EGF receptor
was administered orally at t ¼ 0. Once again the model
parameterisation is given in Tables 1 and 2. We sought to
reduce the PBPK model via balanced truncation whilst
seeking to preserve accuracy in the intravenous and brain
compartments. In order to maintain sufficient accuracy in
the brain compartment reduction via balanced truncation
required the retention of 4 state-variables in the reduced
PBPK model. This yielded a maximal relative error across
both the intravenous and brain compartments of 4.9, 3.8,
and 9.2% in modelling the pharmacokinetics of pindolol,
midazolam, and thiopental respectively.
The reduced PBPK model was then linked to the reduced
ERK activation model by defining the output of the PBPK
(concentration of the drug in the brain) to represent the input
of the ERK activation model (the extracellular concentration
of an antagonist that binds with and inhibits the EGF
receptor). Employing the 11 dimensional version of the
ERK-activation model and 4 dimensional PBPK model
yielded the results given in Fig. 7. Here we simulated the
system for doses of 30 mg of hypothetical ERK antagonists
Fig. 6 Simulated time courses
for the total concentration of the
phosphorylated forms of
chemotactic protein CheY under
the original and reduced PBPK
linked chemotaxis models after
oral administration of a 150 mg
dose of a hypothetical
chemotactic attractant. Drug
specific parameters are
represented by pindolol,
midazolam and thiopental.
Physiological parameters were
taken to represent a 70 kg male
human with average measures
of liver and kidney function,
fractional tissue volumes and
blood flow. Parameters are
detailed in Tables 1 and 2
Table 5 Maximal relative error e results for the reduction of the ERK
activation model via proper lumping
Dimension Lumping error (%)
75  0
50 0.01
25 0.52
15 1.26
14 2.21
13 2.29
12 1.21
11 3.07
10 6.02
9 10.96
8 13.12
7 14.18
6 29.53
5 39.03
4 46.47
3 54.67
2 53.52
1 55.73
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using the respective model parameterisations for pindolol,
midazolam, and thiopental. This yielded a maximal relative
error e of 1, 4.2, and 5.9% for pindolol, midazolam and
thiopental, respectively. Overall this resulted in a reduction
between the unreduced linked model and the reduced linked
model from 115 state-variables to 15 and a speed up in
simulation time, under Matlab’s inbuilt ode45 numerical
solver, from an average of 1.764 to 0.541 s. Matlab files
detailing the reduction of the ERK activation model have
been made available in Additional file 2 - ERK Activation
Reduction Files, use of these files requires the Matlab
Symbolic package.
Conclusions
This article has provided an account of how a model of
PBPK can both be reduced and linked to systems biology
type models describing target scale responses to drug
administration. Doing so yields a model of enhanced
pharmacodynamics or QSP that describes drug adminis-
tration, metabolism, and action across multiple scales.
Crucial to the practical use of such systems is the
application of model reduction methods, such as lumping
and balanced truncation. Without such methods, models
will typically be highly complex and intractable in the
context of clinical trial data. However, as has been
demonstrated throughout this paper these approaches can
enable the construction of significantly simplified systems
that still accurately replicate the model’s original beha-
viour. These models are then sufficiently simplified to be
informed by and fitted against clinical trial data whilst
maintaining their descriptive power across multiple scales.
This paper has focused specifically on the methods of
balanced truncation and lumping for their ability to pre-
serve input–output behaviour in reduced systems across a
range of inputs. Balanced truncation was employed for the
decomposed linear components of the network due to its
superior properties in this regard, whilst lumping is
employed for the nonlinear components. Other methods
such as time-scale analysis or sensitivity analysis based
approaches (outlined in much greater detail in our recent
review paper [47]) could also have been considered, but
their specific emphases and approaches make them less
obvious choices. Throughout the paper we have sought to
show how the methods might be best deployed in parallel,
by aiming to decompose the overall model based upon the
property of linearity and then applying each method due to
its suitability based upon this criterion.
We compared the use of balanced truncation in reducing
PBPK models to the more commonly applied method of
proper lumping. It was demonstrated that balanced trun-
cation can produce a more accurate reduced system than
lumping. Additionally, the method is also guaranteed to
produce reduced systems that reproduce the input–output
behaviour not only locally to the tested inputs, but globally.
As a result it represents an excellent choice for reducing the
overall ‘gateway’ of the model—the point at which the
Fig. 7 Timecourses for the total
concentration of the
phosphorylated forms of ERK
under the original 115
dimensional and the reduced 15
dimensional PBPK linked ERK
activation models after oral
administration of a hypothetical
EGFR antagonist. Here we
simulated the system for doses
of 30 mg of a hypothetical ERK
antagonist represented by the
drug specific parameterisations
of pindolol, midazolam, and
thiopental
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main input, dosing, interacts with the system. The down-
side is that this approach somewhat obfuscates the meaning
of the compartments in the reduced system. As a result, it is
best employed in situations where a ‘black-box’ reduced
system is acceptable; more specifically, it is most appro-
priate in situations where the structure of the reduced
model is not of crucial importance, but the accuracy of its
predictions as compared with the original model are.
Whilst the linkedmodels created by the approachdescribed
in this paper have a wide range of potential benefits, there also
exist a number of current limitations to their application. In
particular, validation of such models is challenging; whilst
clinical trials often collect data on intravenous drug concen-
tration over time and data on the clinical endpoints observed,
in vivo data on the dynamics of the subcellular species is
typically not available. Additionally, mechanistically mod-
elling how subcellular effects map to the clinical outcomes
observed at the whole-body scale may require further mod-
elling efforts. At a simpler level, even questions such as what
degreeof error shouldbe tolerated inmodel reduction andhow
to select the most appropriate reduced model for a specific
application remain unanswered.
Finally, the question of how best to link the intracellular
and pharmacokinetic scales remains an important one. The
method presented here seeks to couple the models in such a
way that the outputs of one model can be treated as the
inputs of the other, and vice versa. By using automated
methods of reduction guaranteed to maintain the input–
output behaviour across a reasonable range of inputs, this
approach will give accurate reduced linked models. How-
ever, the specific form and extent of the inputs and outputs
that it is necessary to define to achieve this coupling will
end up limiting and defining the reduction it is possible to
achieve. In short the overall reduction obtainable is likely
to be improved the fewer points of coupling are required.
Whilst reduction is likely to perform better the fewer inputs
and outputs are defined, and the examples given in this
paper possess only a single input and single output, the
overall methodology remains valid for the general case of
any number of defined inputs and outputs.
Irrespective of these limitations, however, the value of
employing model reduction and linking in the construction
of QSP models should not be understated. This approach
enables us to start with pre-existing physiologically based
models at multiple scales of drug activity and construct
integrated, reduced models that maintain a mechanistic
basis, but that are of a tractable scale. Through the use of
model reduction, it is possible to shrink both the parameter
space and the number of state-variables modelled. In
combination with the often substantial speed-ups in simu-
lation times observed, these approaches can make a range
of computational approaches (including parameter fitting)
more attainable. By selectively applying model reduction
to specific portions of a network it is further possible to
produce simplified systems that maintain physiological,
molecular-scale detail for specific mechanisms of interest.
The influence of the remainder of the system can be
accounted for with a lesser degree of specificity. These
directly reduced networks enable the study of specific
forms of parameter variation including, for example, how
patient variability at the level of protein expression might
feed through to differences in dose-response. Overall, the
approach outlined in this paper can be seen as providing a
route to models that contain a medium level of granularity
between the fully systemic level of modern approaches and
the more empirical classical approaches, whilst still
maintaining a physiological basis in model interpretability.
By providing the tools to predict differences in patient
response and consider optimal dosing strategies in a more
mechanistic light, this can be seen as one stepping stone
towards the ultimate goal of personalised medicine.
We feel that methods of model reduction have a vital
role to play in the continuing development of QSP and that
the topics discussed in this paper are fertile ground for
future research. Where researchers now seek to quantita-
tively describe drug action in more complete terms than
historical approaches allow, it is necessary that we reflect
on the perennial issue of model complexity and the
preservation of practical applicability.
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Appendix
Appendix 1: The Petrov–Galerkin projection
Methods ofmodel reduction can be considered as a projection
of the state-variables to a lower dimensional subspace V :
dim Vð Þ ¼ n^ of the original phase-space, within which some
relevant set of the system’s trajectories can be adequately
approximated. Mathematically, applying such a projection to
obtain a reduced dynamical system is underpinned by the
Petrov–Galerkin projection which will be introduced here.
Consider a basis B of the subspace V such that
B ¼ b1; . . .; bn^½  2 Rnn^. Assuming B has been selected
such that it provides an adequately accurate approximation
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of the original state-variables xðtÞ within the subspace V,
then
xðtÞ  B~xðtÞ ð6Þ
with ~xðtÞ 2 Rn^ representing the reduced set of state-vari-
ables. Substituting this approximation into the original
model form yields
B
d~x
dt
¼ f ðB~xðtÞÞ þ
Xl
i¼1
giðB~xðtÞÞuiðtÞ þ qðtÞ ð7Þ
where it is assumed that B is time-invariant. Additionally,
qðtÞ 2 Rn is termed the residual and addresses the dis-
crepancy emerging from the fact that B~x is typically not an
exact solution of the system for all times.
Now letW represent a subspace that is orthogonal to the
residual qðtÞ with a basis C 2 Rnn^ such that C|qðtÞ ¼ 0
(where | represents the standard definition of the trans-
pose). Hence, left multiplying Eq. (7) by C| produces
C|B
d~x
dt
¼ C|f ðB~xðtÞÞ þ
Xl
i¼1
C|giðB~xðtÞÞuiðtÞ ð8Þ
Assuming C|B is non-singular, this finally leads to a
reduced dynamical system of the form
d~x
dt
¼ C|Bð Þ1C|f ðB~xðtÞÞ þ
Xl
i¼1
C|Bð Þ1C|giðB~xðtÞÞuiðtÞ:
ð9Þ
This simplification of a dynamical system to a lower
dimensional subspace is known as the Petrov–Galerkin
projection. In the special case where B ¼ C it is known
simply as the Galerkin projection. In that case
B|Bð Þ1B| ¼ B ð10Þ
Such that B is a generalised left inverse of B and BB ¼ In^
(the n^ dimensional identity matrix).
Whilst the explanation given above provides an expla-
nation of how to apply a Petrov–Galerkin projection, it
does not provide a methodology for finding suitable bases
B and C for a given model. It is methodologies of this kind
that comprise the majority of the model reduction
literature.
Appendix 2: Lumping
For a general system of ODEs of the form represented by
Eq. (1), a lumping is some mapping L : Rn ! Rn^ of the
original state variables xðtÞ 2 Rn to a reduced set ~xðtÞ 2 Rn^
where n^\n. In the case of a linear lumping this can be
expressed as a projection of the form
~xðtÞ ¼ LxðtÞ: ð11Þ
In the case of a proper lumping this projection L becomes a
matrix L 2 0; 1f gn^n where each column is pairwise
orthogonal, implying that each of the original state-vari-
ables corresponds to, at most, one of the lumped state-
variables in the reduced model.
Given the operator L, the dynamics of the reduced
variables ~xðtÞ can be obtained via a Galerkin projection
(see Appendix 1) applied to the original system, such that
_~xðtÞ ¼ Lf ðL~xðtÞÞ þ
Xl
i¼1
LgiðL~xðtÞÞuiðtÞ;
with ~xð0Þ ¼ ~x0 ¼ Lx0;
ð12aÞ
yðtÞ ¼ hðL~xðtÞÞ; ð12bÞ
where L 2 Rnn^ represents a generalised right inverse of L
such that LL ¼ In^, In^ the n^ n^ identity matrix. An
approximation for the original state variables from the
reduced variables can be computed as
xðtÞ  L~xðtÞ: ð13Þ
L can be any generalised right-inverse of L and, as such,
there exists an infinite number of ways to construct this
matrix, with the specific choice affecting the error incurred
by the reduced model. In this paper we follow the approach
of the original lumping papers by Wei and Kuo [25, 62]
which suggest selecting the generalised inverse L that
reconstructs the steady-state of the system such that xðtÞ ¼
L~xðtÞ for t !1. This can be constructed as
L ¼ XL| LXL|ð Þ1; ð14Þ
and
X :¼ diag xf g
and x represents the steady-state of the system such that
limt!þ1 xðtÞ ¼ x.
Appendix 3: Balanced truncation
The application of balanced truncation begins with a con-
trolled, linear system of the form described by Eq. (2).
Given such a form, we then proceed by calculating two
matrices known as the controllability and observability
Gramians (P and Q, respectively) for the system. These
can be obtained via solving the following Lyapunov
equations,
AP þ PA| þ BB| ¼ 0;
A|QþQAþ C|C ¼ 0:
Balanced truncation then requires the computation the
balancing transformation, which equalises and diagonalises
these matrices. This can be computed in a numerically
Journal of Pharmacokinetics and Pharmacodynamics
123
stable manner by following the proceeding steps; first,
perform a Cholesky factorisation of both of the Gramians
to give
P ¼ L|L; and Q ¼ R|R:
Now take a singular value decomposition of the newly
formed matrix LR| to obtain
LR| ¼ URV|;
using this, the balancing transformation T and its inverse T
can be computed as
T ¼ R12V|R and T ¼ L|UR12:
Given a reduced dimensionality n^ the reduced model can
be constructed via the following transformations
x! ~x ¼ PTx;
A! ~A ¼ PTATP|;
B! ~B ¼ PTB;
C ! ~C ¼ C TP|;
Where P is an n^ n matrix of the form P ¼ In^0½ . This
gives a reduced, n^ dimensional model of the form
_~x ¼ ~A~xþ ~Bu;
y ¼ ~C~x:
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